Events & Presentations

Date	Event Details	Remind Me
Apr 3 - Apr 4, 2023	7th Complement UK Training Course and Symposium	Add to Outlook Add to Google Calendar

Date	Event Details
May 7, 2020 4:30 PM EDT	Arrowhead Pharmaceuticals 2020 Second Quarter Results Listen to webcast Supporting Materials: Prepared Remarks 210.2 KB
Mar 18, 2020 4:00 PM EDT	Oppenheimer 30th Annual Healthcare Conference Location: New York View Additional Information Conference Presentations cancelled due to COVID-19
Mar 17, 2020 2:00 PM EDT	5th Annual Oligonucleotide & Precision Therapeutics Congress Location: Cambridge View Additional Information Conference Presentations cancelled due to COVID-19
Mar 11, 2020 11:15 AM EDT	Barclays Global Healthcare Conference Listen to webcast Location: Miami View Additional Information Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will participate in a hybrid podium/fireside chat presentation
Feb 5, 2020 4:30 PM EST	Arrowhead Pharmaceuticals 2020 First Quarter Results Listen to webcast
Dec 10, 2019 6:00 PM HST	HEP DART 2019 Supporting Materials: View Presentation 6.4 MB View Additional Information Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver an oral presentation titled, “Where will RNAi fit in the era of finite therapies”
Dec 3, 2019 11:00 AM EST	Piper Jaffray 31st Annual Healthcare Conference View Additional Information Fireside chat cancelled Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation with Edward Tenthoff, managing director and senior research analyst at Piper Jaffray
Nov 25, 2019 4:30 PM EST	Arrowhead Pharmaceuticals 2019 Year End Results Listen to webcast Supporting Materials: Prepared Remarks 191.4 KB
Nov 18, 2019	American Heart Association Scientific Sessions 2019 Supporting Materials: RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects 867.9 KB RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides 493.1 KB Location: Philadelphia View Additional Information November 18, 9:32 a.m. EST – Dr. Christie Ballantyne, Baylor Coll Med, Houston, TX, will deliver an oral presentation titled, “RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides” November 18, 9:38 a.m. EST – Dr. Gerald Watts, Univ of Western Australia, Royal Perth Hosp, Perth, Australia, will deliver an oral presentation titled, “RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects”
Nov 8 - Nov 12, 2019	The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) Supporting Materials: Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t)ide Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B 226.2 KB First Clinical Experience with RNA Interference-based Triple Combination Therapy in Chronic Hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos(t)ide Analogue 199.1 KB Location: Boston View Additional Information Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t)ide Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B Publication Number: 0696 Session: Hepatitis B - Therapeutics: New Agents Session Date and Time: November 8, 2019 from 8:00 AM to 5:30 PM EST Location: Hynes Convention Center, Hall B Authors: Edward Gane, et al. FIRST CLINICAL EXPERIENCE WITH RNA INTERFERENCE [RNAi]-BASED TRIPLE COMBINATION THERAPY IN CHRONIC HEPATITIS B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) AND A NUCLEOS(T)IDE ANALOGUE (NA) Publication Number: LP4 Session: Late-Breaking Poster Session Session Date and Time: November 11, 2019 from 8:00 AM to 5:30 PM EST Location: Hynes Convention Center, Hall B Authors: Man-Fung Yuen, et al.